Sold as Wytensin. Every FDA application for this active ingredient: 1 branded and 4 generic.
As of Nov 14, 2026, FDA lists 5 applications for Guanabenz Acetate (sold as Wytensin), first approved Sep 7, 1982, with 0 new uses approved and 0 published complete response letters.
| Sep 7, 1982 | WytensinNDA 18587 ยท New molecular entity | Wyeth Ayerst | 20 | Discontinued |
| Feb 28, 1994 | Guanabenz AcetateANDA 74025 | Watson Labs | 4 | Discontinued |
| Jun 1, 1994 | Guanabenz AcetateANDA 74267 | Ani Pharms | 4 | Discontinued |
| Apr 7, 1995 | Guanabenz AcetateANDA 74149 | Ani Pharms | 8 | Discontinued |
| Sep 30, 1998 | Guanabenz AcetateANDA 74517 | Chartwell Rx | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
